• Earnings per share of $4.40, beating the estimated $4.37.
• Revenue reached approximately $1.12 billion, surpassing the $1.07 billion estimate.
• Strong financial position with a debt-to-equity ratio of 0.007 and a current ratio of approximately 5.60.

argenx SE, trading under the symbol ARGX on both Euronext and Nasdaq, is a global leader in immunology. The company focuses on developing innovative therapies for severe autoimmune diseases. Its competitors include other biotech firms like Alexion Pharmaceuticals and Horizon Therapeutics. ARGX's recent financial performance highlights its strong market position and growth potential.

On October 30, 2025, ARGX reported earnings per share of $4.40, surpassing the estimated $4.37. The company achieved a revenue of approximately $1.12 billion, exceeding the estimated $1.07 billion. This performance is supported by $1.13 billion in global product net sales for the third quarter of 2025, as highlighted by the company's financial results.

argenx is on track to submit a supplemental Biologics License Application (sBLA) for seronegative generalized myasthenia gravis (gMG) by the end of the year. The company plans to report results from the ADAPT-OCULUS study in the first half of 2026, aiming for the broadest myasthenia gravis label of any biologic. This aligns with their commitment to innovation and patient impact, as emphasized by CEO Tim Van Hauwermeiren.

The company anticipates five registrational study readouts in 2026 from its leading immunology pipeline. ARGX's expansion with VYVGART in two blockbuster indications and the advancement of five registrational programs further demonstrate its growth strategy. The management will host a conference call to discuss these updates, reflecting their proactive communication with stakeholders.

Financially, ARGX has a price-to-earnings (P/E) ratio of approximately 36.57, indicating investor confidence. Its price-to-sales ratio is about 13.74, and the enterprise value to sales ratio is around 13.19, reflecting strong market valuation. With a debt-to-equity ratio of 0.007 and a current ratio of approximately 5.60, ARGX maintains a strong financial position, ensuring stability and growth potential.